Patients on Ozempic-class drugs: a risk modifier in perio, not a treatment

GLP-1 receptor agonists (GLP-1RAs), the now-ubiquitous semaglutide-class drugs for type 2 diabetes and obesity, are appearing in a growing share of periodontal patients. This narrative review, conducted under SANRA and ICMJE criteria, asks what that means chairside, mapping mechanisms, preclinical data and the still-scarce human evidence.

Two pathways might link these drugs to periodontal tissues. The indirect route runs through better glycemic control, weight loss and reduced systemic inflammation, the same metabolic levers that shape periodontal risk. The direct route involves GLP-1 receptor signaling and the GLP-1/DPP-4 axis acting on the tissues themselves. Preclinical studies are consistent and encouraging: in models of hyperglycemia or inflammation, GLP-1RAs reduced inflammation, dampened osteoclast activity and alveolar bone loss, and improved periodontal stem-cell function, via NF-kappaB, Wnt/beta-catenin and MAPK pathways. Animal implant studies, including local exendin-4 delivery platforms, point to osteometabolic benefits around fixtures.

Honest caution dominates the clinical message: human data are limited and mostly observational, entangled with confounders such as metabolic status, smoking, concurrent medication and nutrition. Oral side effects such as xerostomia and dehydration also deserve attention, since reduced salivary flow is not trivial for periodontal and caries risk. The authors' conclusion is rightly measured: today, GLP-1RA therapy should be regarded as a contextual modifier of periodontal risk and healing capacity, not a stand-alone periodontal therapy. For the clinician the practical value is awareness, recognizing that a patient on a GLP-1RA may have a different metabolic and salivary profile, factoring it into risk assessment and maintenance, while resisting the temptation to overstate a benefit that human evidence has not yet demonstrated.